Apotex Launches Generic Ozempic Alternative in Canada
Event summary
- Apotex Inc. launched Apo-Semaglutide Injection™, a generic equivalent of Ozempic®, in Canada on May 14, 2026.
- The product is available in 2 mg and 4 mg prefilled pen formats, offering doses of 0.25 mg, 0.5 mg, and 1 mg.
- Apo-Semaglutide Injection is indicated for the once-weekly treatment of type 2 diabetes mellitus.
- The launch follows Health Canada's standard regulatory review for peptide medicines, developed in partnership with Orbicular Pharmaceutical Technologies.
The big picture
Apotex's launch of a generic semaglutide injection underscores the growing competition in the GLP-1 receptor agonist market, particularly for diabetes treatments. This move aligns with broader industry trends toward cost-effective alternatives to high-priced branded drugs, potentially reshaping the Canadian pharmaceutical landscape. The strategic partnership with Orbicular Pharmaceutical Technologies highlights the importance of collaborative development in bringing complex generics to market.
What we're watching
- Market Penetration
- How quickly Apo-Semaglutide Injection will gain market share against branded Ozempic® in Canada.
- Regulatory Dynamics
- Whether Health Canada's approval process for peptide medicines will impact future generic launches.
- Pricing Strategy
- The extent to which Apotex's pricing will drive broader access to semaglutide treatments.
Related topics